1[1]Anderson J L, Carlquist J L, Muhlestein JB, et al. Marker and infectious serology as risk factors for coronary artery disease and myocardial infarction[J ]. J Am Coll Cardiol, 1998,32: 35 - 41
2[2]Sera Y,Kanda T,Tanka T, et al. Interleukin 18 in acute myocardial infarction [ J ]. Heart, 2000,84: 668-669
3[3]Maseri A. Inflammation, atherosderosis and isehemie events- exploring the hidden side of moon[J ]. N Engl J Med, 1997,336:1014- 1016
4[4]Linnanmaki E, Leimonen M, Mattilak, et al. Presence of chylamydia pneumoniae - specific antibodies in circulating immune complexes in coronary heart disease[ J ]. Circulation, 1993,87:1130 - 1134
5[5]Azar RR, Mckay, Kiernar F J, et al. Coronary angioplasty induces a systemic inflammatory response[J ].Am J Cardiol, 1997,80( 11 ): 1476
6Lea AP, Mctavish D, Atoraatatin. A review of its pharmaeolog and therapetutic potential in the management of hyperlipidemias [ J ]. Drugs, 1997, 53:828-847.
7Wiviott SD, De Lemos JA, Connon CP, et al. A tale of two trials: a comparison of the post - acute coronary syndrome lipid - lowering trials A to Z and PROVE IT - TIMI 22 [ J]. Circulation, 2006, 113 ( 11 ) : 1406 - 1414.
8Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on earlyrecurrent ischemic events in acute coronary syndromes : the MIRACL study: arandomized controlled trial [ J]. JAMA, 2001, 285: 1711 -1718.
9Ranoof MA, Iqbalk, Miy MM, et al. Measurement of plasma lipids in patients admitted with acute myocardial infarction or unstable angina pectoris [J]. Am J Cardid, 2001, 88: 165-167.
